Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$55.3M Buy
820,479
+122,321
+18% +$8.15M 6.8% 5
2026
Q1
$43.8M Buy
698,158
+276,558
+66% +$19.3M 6.15% 8
2025
Q4
$28M Buy
+421,600
New +$27.3M 3.63% 14
2023
Q4
Sell
-267,380
Closed -$24.9M 30
2023
Q3
$24.9M Buy
267,380
+215,582
+416% +$24.3M 7.98% 3
2023
Q2
$6.66M Buy
+51,798
New +$6.26M 2.47% 15

Other funds holding DXCM

Tri Locum Partners's DXCM Position: Q2 2026 in Review

Tri Locum Partners increased its DexCom (DXCM) stake by 18% in Q2 2026, buying an estimated $8.15M and bringing the position to 820,479 shares worth $55.3M. The position accounts for 6.8% of the portfolio, ranked #5.

Tri Locum Partners first reported a position in DXCM in Q2 2023 and has held it in 5 quarters since. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Tri Locum Partners held 820,479 shares of DexCom worth $55.3M as of Q2 2026.
  • Tri Locum Partners bought 122,321 DexCom shares in Q2 2026, an estimated $8.15M.
  • DexCom made up 6.8% of Tri Locum Partners's portfolio in Q2 2026, its #5 holding.
  • Tri Locum Partners first reported a position in DexCom in Q2 2023 and has held it in 5 quarters since.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Tri Locum Partners's 13F filing for Q2 2026, filed 14 Aug 2026.